Blog | HemaCare

Mobilized HemaCare Leukopaks Aid New T Cell Therapy Development

Feb 4, 2020 10:06:00 AM / by Nancy Andon, MSc posted in Cell Therapy, T Cells

0 Comments

"File:Lab mouse mg 3216.jpg" by Rama is licensed under CC BY-SA 2.0

A recent publication out of UCLA cites using HemaCare mobilized leukopaks in the development of a new natural killer (NK) T cell-based therapy. [1]

The multi-departmental group of scientists, the majority of whom are based at UCLA, collaborated on the groundbreaking cancer research project. Their potential treatment relies on the unique properties of a powerful class of natural killer T cells.

Read More

The Promise of Stromal Cells (Mesenchymal Stem Cells)

Jan 28, 2020 10:07:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Bone Marrow, Cell Therapy, Stem Cells

0 Comments

Stromal cells are becoming a viable candidate for cell therapy due to their immunosuppressive properties and ability to treat autoimmune diseases.

Advances in the development of treatments for autoimmune diseases and tissue repair are being realized through cell therapy approaches. Research is ongoing to overcome common limitations to successful clinical use, such as transplantation rejection and low therapeutic efficacy. Stromal cells, or mesenchymal stem cells, are becoming a very viable candidate for cell therapy due to their unique characteristics in comparison to other stem cell types. Mesenchymal stem cells (MSCs) are pluripotent stem cells that are self-renewable; however, they have immunomodulatory features that increase the success of their utility for immune disease therapy and regenerative medicine.

Read More

Could Cell Therapy Boost Cardiac Function in DMD Patients?

Jan 14, 2020 10:06:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Bone Marrow, Cell Therapy, Stem Cells

0 Comments

Mesenchymal Stem cells (MSCs) derived from mouse muscle tissue and bone marrow were used in an experimental cell therapy for Duchenne Muscular Dystrophy.

Duchenne muscular dystrophy (DMD) is an incurable, progressively debilitating muscular-skeletal and cardiac disease caused by a mutation in the dystrophin gene. The encoded dystrophin protein is part of a larger protein complex involved in anchoring the muscle cytoskeleton to components of the extracellular matrix. Loss of dystrophin leads to muscle wasting, and heart disease is a major cause of death in patients with DMD. Therefore, the availability of effective treatments to address cardiac function in people with DMD is vital.

Read More

HemaCare Publication Highlights Role of Cell Therapy Starting Materials

Jan 7, 2020 10:04:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy

0 Comments

HemaCare Corporation’s latest publication in BioPharm International [1] sheds light on a topic that has been preoccupying some of the best minds in cell therapy research; the need to ensure a reliable supply of top-notch starting materials for up-and-coming cell and gene therapies.

Unlike traditional medical treatments, the raw materials for these therapies cannot simply be manufactured. Instead, the supply of starting materials relies on a steady influx of voluntary donors willing to take the time to undertake a fairly complex screening process and donate peripheral blood or bone marrow for altruistic reasons. Nor is a reliable donor pool the only criteria necessary to supplying materials for a successful cellular therapeutic. Starting material quality and consistency ultimately determine the reliable efficacy of the final product.

Read More

Nanotechnology for Acute Kidney Injury

Dec 30, 2019 10:06:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cell Therapy, Drug Discovery

0 Comments

While there is no cure for acute kidney injury, a research team out of the University of Wisconsin-Madison may be shedding some new light on this condition.

Acute kidney injury (AKI) is characterized by a sudden decline in kidney function. This decline is marked by a significant rise in serum creatinine levels that may be accompanied by a reduction in urine output. Some cases of AKI require kidney transplantation or can lead to death. There are a number of causes of AKI, including injury from gadolinium-based contrast agents (nephrogenic systemic fibrosis), rhabdomyolysis, low blood volume, and vasculitis.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts